PUBLISHER: iData Research Inc. | PRODUCT CODE: 1328967
PUBLISHER: iData Research Inc. | PRODUCT CODE: 1328967
The European market for dental bone graft substitutes and other biomaterials attained a value of €319.3 million in 2022. Projections indicate an upward trajectory, with an anticipated CAGR of 3.7%, reaching €411.6 million during the forecast period. Leading the market are three key contenders: Geistlich, botiss biomaterials, and ZimVie.
In the course of this comprehensive medical market research, we scrutinized over 50 companies across Europe. Employing our meticulous methodology, we gained insights into market sizes, unit sales, company market shares, and crafted precise forecasts. The comprehensive report suite on the Latin American market encompasses dental bone graft substitutes, dental growth factors, dental barrier membranes, local antimicrobial periodontal treatment, and dental soft tissue regeneration.
The expansion of the overall dental bone graft substitutes (DBGS) and biomaterials market is propelled by the consistent demand in dental implant procedures. Although the dental implant market is more mature in Europe compared to the dental biomaterials sector, the wider acceptance of dental grafts and biomaterials is escalating due to advancements in dental implantology and the formulation of novel treatment protocols. In recent years, there has been a notable surge in dental implant procedures, driven both by patient demand and an increasing number of general practitioners offering these services. This surge is consequently energizing the entire DBGS and biomaterials market.
In 2022, Geistlich emerged as the dominant player in the overall European DBGS and other biomaterials market, primarily due to its significant shares in both the DBGS and DBM segments. Geistlich's foothold in the DBGS market is particularly attributed to its robust presence in the xenograft sector. In the same year, botiss biomaterials secured the second-largest market share in the European DBGS and biomaterials market. This achievement can be attributed to its strategic partnership with Straumann Group. The collaboration between the two companies, which began in 2014 and saw Straumann Group acquire a 30% stake in botiss biomaterials in July 2018, synergized Straumann's leadership in the European dental implant market with botiss' strong position in the DBGS market. Meanwhile, ZimVie held the third-ranking position in the total DBGS and biomaterials market in 2022, driven by its robust presence across segments including bone graft substitutes, dental membranes, and dental soft tissue regeneration within the European market.
List of Charts
List of Figures Figure 1-1: Dental Bone Graft Substitute and Other Biomaterials Market Share Ranking by Segment, Europe, 2022